MedTrace Logo

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03844074 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2025-03-19

No results posted yet for this study

Summary

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

Conditions

  • Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Wet Macular Degeneration

Interventions

BIOLOGICAL

bevacizumab

1.25 mg, intravitreal injection

BIOLOGICAL

ranibizumab

0.5mg, intravitreal injection

Sponsors & Collaborators

  • Outlook Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer M Kissner, PhD · Outlook Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-07-23
Completion
2020-08-13
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03844074 on ClinicalTrials.gov